Comparison of the costs of HPV testing through community health campaigns versus
home-based testing in rural Western Kenya: a microcosting study.
BMJ Open 2020;
10:e033979. [PMID:
33109637 PMCID:
PMC7592277 DOI:
10.1136/bmjopen-2019-033979]
[Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/10/2019] [Revised: 07/29/2020] [Accepted: 09/21/2020] [Indexed: 11/04/2022] Open
Abstract
OBJECTIVES
To estimate the cost of human papillomavirus (HPV)-based screening through community health campaigns (CHCs) and home-based testing.
SETTING
CHCs and home-based testing in six communities in rural Western Kenya.
PARTICIPANTS
CHCs and home-based screening reached 2297 and 1002 women aged 25-65 years, respectively.
OUTCOME MEASURES
Outcome measures were overall cost per woman screened achieved through the CHCs and home-based testing and the cost per woman for each activity comprising the screening intervention.
RESULTS
The mean cost per woman screened through CHCs and home-based testing were similar, at $37.7 (range $26.4-$52.0) and $37.1 (range $27.6-$54.0), respectively. For CHCs, personnel represented 49% of overall cost, supplies 25%, services 5% and capital goods 23%. For home-based testing, these were: personnel 73%, supplies 25%, services 1% and capital goods 2%. A greater number of participants was associated with a lower cost per participant.
CONCLUSIONS
The mean cost per woman screened is comparable for CHC and home-based testing, with differences in type of input. The CHCs generally reached more eligible women in the six communities, whereas home-based strategies more efficiently reached populations with low screening rates.
TRIAL REGISTRATION NUMBER
NCT02124252.
Collapse